Fig. 6: NOXA deletion protects TNBC from PTX and BH3-mimetic co-treatment. | Cell Death & Disease

Fig. 6: NOXA deletion protects TNBC from PTX and BH3-mimetic co-treatment.

From: The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents

Fig. 6

Parental and two NOXA-KO clones of each TNBC cell line were treated with or without 5000 nM of the indicated BH3-mimetics alone (DMSO) or in combination with 20 or 50 nM PTX for 48 h. Heatmaps are showing the mean value of metabolic activity assessed with MTT-assay. A MDA-MB-231 (n = 5), B HS-578-T (n = 4), C Cal-51 (n = 5).

Back to article page